Pharmaceutical composition for adjunctively treating cancer

Abstract

The present invention provides a pharmaceutical composition for adjunctively treating cancer. Differing from conventional therapies commonly using anti-cancer drugs and/or radiation substances to cause the apoptosis of cancer cells, the present invention particularly adopts an ethanol extract of Taiwanofungus camphorata (TCEE), an ethanol extract of Ganoderma lucidum (GLEE) or a combination of the TCEE and the GLEE as the a novel pharmaceutical composition for causing the apoptosis of lung cancer cells A594, hepatoma cells Huh 7, breast cancer cells MDA-MB 231, and colorectal cancer cells HT 29. Moreover, differing from conventionally-used anti-cancer drugs and radiation substances always causing some side-effects such as nausea, vomit, and poor appetite, this novel pharmaceutical composition can not only be used for adjunctively treating cancer, but also possesses many healthy effects, including: detoxification, enhancing immunity, and increasing appetite.

What is claimed is: 
     
         1 . A pharmaceutical composition for adjunctively treating cancer, being an  Taiwanofungus camphorata  extract; wherein a specific dose of the pharmaceutical composition in a range from 50 μg/mL to 250 μg/mL shows a therapeutic effect to a specific cancer. 
     
     
         2 . The pharmaceutical composition for adjunctively treating cancer of  claim 1 , wherein the  Taiwanofungus camphorata  extract is selected from the group consisting of: water extract of  Taiwanofungus camphorata  and ethanol extract of  Taiwanofungus camphorata.    
     
     
         3 . The pharmaceutical composition for adjunctively treating cancer of  claim 1 , wherein the specific cancer is selected from the group consisting of: lung cancer, liver cancer, breast cancer, and colorectal cancer. 
     
     
         4 . The pharmaceutical composition for adjunctively treating cancer of  claim 3 , wherein the pharmaceutical composition is able to lower the cell viability of a specific cancer cell down to 50%, and the specific cancer cell is selected from the group consisting of: lung cancer cell A549, liver cancer cell Huh 7, breast cancer cell MDA-MB 231, and colorectal cancer cell HT 29. 
     
     
         5 . A pharmaceutical composition for adjunctively treating cancer, being a  Ganoderma lucidum  extract; wherein a specific dose of the pharmaceutical composition in a range from 50 μg/mL to 250 μg/mL shows a therapeutic effect to a specific cancer. 
     
     
         6 . The pharmaceutical composition for adjunctively treating cancer of  claim 5 , wherein the  Ganoderma lucidum  extract is selected from the group consisting of: water extract of  Ganoderma lucidum  and ethanol extract of  Ganoderma lucidum.    
     
     
         7 . The pharmaceutical composition for adjunctively treating cancer of  claim 5 , wherein the specific cancer is selected from the group consisting of: lung cancer, liver cancer, breast cancer, and colorectal cancer. 
     
     
         8 . The pharmaceutical composition for adjunctively treating cancer of  claim 7 , wherein the pharmaceutical composition is able to lower the cell viability of a specific cancer cell down to 50%, and the specific cancer cell is selected from the group consisting of: lung cancer cell A549, liver cancer cell Huh 7, breast cancer cell MDA-MB 231, and colorectal cancer cell HT 29. 
     
     
         9 . A pharmaceutical composition for adjunctively treating cancer, being a combination extract of an  Taiwanofungus camphorata  extract and a  Ganoderma lucidum  extract; wherein a specific dose of the pharmaceutical composition in a range from 50 μg/mL to 250 μg/mL shows a therapeutic effect to a specific cancer. 
     
     
         10 . The pharmaceutical composition for adjunctively treating cancer of  claim 9 , wherein the  Taiwanofungus camphorata  extract is a water extract of  Taiwanofungus camphorata  or an ethanol extract of  Taiwanofungus camphorata , and the  Ganoderma lucidum  extract is a water extract of  Ganoderma lucidum  or and ethanol extract of  Ganoderma lucidum.    
     
     
         11 . The pharmaceutical composition for adjunctively treating cancer of  claim 9 , wherein the  Taiwanofungus camphorata  extract and the  Ganoderma lucidum  extract have a specific combining ratio, and the specific combining ratio is in a range from 1:11 to 10:1. 
     
     
         12 . The pharmaceutical composition for adjunctively treating cancer of  claim 9 , wherein the specific cancer is selected from the group consisting of: lung cancer, liver cancer, breast cancer, and colorectal cancer. 
     
     
         13 . The pharmaceutical composition for adjunctively treating cancer of  claim 12 , wherein the pharmaceutical composition is able to lower the cell viability of a specific cancer cell down to 50%, and the specific cancer cell is selected from the group consisting of: lung cancer cell A549, liver cancer cell Huh 7, breast cancer cell MDA-MB 231, and colorectal cancer cell HT 29.